Open AccessLercanidipine and Losartan Effects on Blood Pressure and Fibrinolytic Parameters
Author(s) -
Lin TsungHsien,
Voon WenChol,
Yen HsuehWei,
Huang ChihHsin,
Su HoMing,
Lai WenTer,
Sheu ShengHsiung
Publication year - 2006
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/s1607-551x(09)70304-3
Subject(s) - lercanidipine , medicine , losartan , fibrinolysis , blood pressure , fibrinogen , placebo , essential hypertension , pharmacology , cardiology , angiotensin ii , alternative medicine , pathology
Antihypertensive agents may modulate fibrinolysis in addition to reducing blood pressure. We conducted a randomized trial to assess the effects of lercanidipine and losartan on blood pressure (BP) lowering and three fibrinolytic parameters: plasminogen activator inhibitor−1 (PAI‐1), D‐dimer, and fibrinogen. All patients enrolled had essential hypertension and underwent a placebo run‐in period of 2 weeks before randomization to either lercanidipine tablets 10‐20 mg once daily or losartan tablets 50‐100 mg once daily. Twenty‐six patients completed this study. After 8 weeks of treatment, both groups of patients had significantly reduced systolic (SBP) and diastolic BP (DBP) (SBP, p = 0.034 and 0.050, respectively; DBP, p = 0.018 and 0.034 for lercanidipine and losartan, respectively). Both drugs were well tolerated. Only in the group treated with lercanidipine was PAI‐1 concentration significantly reduced (57.1 ± 4.7 to 43.1 ± 4.8 ng/ mL, p = 0.047). No difference was found with D‐dimer and fibrinogen in either group. This study shows that both lercanidipine and losartan are effective antihypertensive drugs in patients with essential hypertension. Lercanidipine may provide additional benefit in fibrinolysis.